FDA adds Darzalex Faspro to combo therapy for newly diagnosed MM
The U.S. Food and Drug Administration (FDA) has approved a new quadruple regimen including Darzalex Faspro (daratumumab and hyaluronidase-fihj) as a first-line approach for adults…
Lindsey Shapiro, PhD, science writer — 
Articles by Lindsey Shapiro
Analyses identify proteins tied to multiple myeloma disease course
Researchers in Germany have identified proteins that could help identify multiple myeloma patients who at high risk for an aggressive disease course and worse…
Blenrep lowers risk of disease progression vs. bortezomib in trial
GSK‘s Blenrep (belantamab mafodotin) cut the risk of cancer progression nearly in half compared with bortezomib when used in combination with other therapies to…
CAR T-cell therapy NXC-201 given orphan drug status in EU
NXC-201, an investigational CAR T-cell therapy, has been designated an orphan drug in the European Union (EU) as a potential treatment of multiple myeloma.
Steroid-free Venclexta combo shows promise in myeloma cells
Combining the cancer therapy Venclexta (venetoclax) with a molecule called 5-azacytidine (5-aza) increased the former’s ability to kill lab-grown cancer cells derived from a range…
Abecma cleared in EU as earlier therapy for hard-to-treat myeloma
The European Commission has approved Bristol Myers Squibb (BMS)’s request to expand the use of the CAR T-cell therapy Abecma (idecabtagene vicleucel) as…
FDA OKs less frequent Tecvayli dosing for treatment responders
The U.S. Food and Drug Administration (FDA) has cleared an every-other-week dosing regimen of Tecvayli (teclistamab) for relapsed or refractory (hard-to-treat) multiple myeloma…
Regeneron seeking approval of linvoseltamab for RRMM in US, EU
The European Medicines Agency has agreed to review Regeneron Pharmaceuticals’ application seeking approval of its investigational therapy linvoseltamab for adults in Europe with relapsed…
Xpovio combo plus mezigdomide to be tested in relapsed-refractory MM
A Phase 1/2 clinical trial will evaluate the safety and efficacy oral mezigdomide, Bristol-Myers Squibb’s investigational treatment, when added to the approved oral…
Vaccine may help boost response to stem cell transplant: Phase 1 trial
A cell-based vaccine designed to promote immune responses against survivin, a protein that helps tumor cells survive and expand, was found to be safe and…
